Immunoglobulin therapy has a wide range of indications, from the treatment of immunodeficiencies
to the control of autoimmune and inflammatory diseases. The number of potential
applications for immunoglobulin therapy continues to expand, and recent research
has highlighted several promising novel uses.
To demonstrate its continued commitment to innovative immunoglobulin research, CSL
Behring has created the Interlaken Leadership Awards.
The Interlaken Leadership Awards program was created to meet the following objectives:
- To identify new clinical applications for immunoglobulin therapy for potential further clinical investigation.
- To further investigate the efficacy and mechanisms of action of polyvalent immunoglobulins.
- To explore novel opportunities to enhance quality of life for patients using polyvalent
The current focus of the Interlaken Leadership Awards program is to advance medical research and knowledge about the potential role
of immunoglobulin therapy in the treatment of neurological disorders.